Junhai Zhen

Dr. Junhai Zhen

zhejiang hospital

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Respiratory Research
Verified
Journal Article
Open access
PDF file
JZJunhai Zhen
Junhai Zhen
YJYan Jing
Yan Jing
CBCao Beibei
Cao Beibei
LLLI LI
LI LI
Background: High flow nasal cannula (HFNC) therapy is widely employed in acute hypoxemic respiratory failure (AHRF) patients. However, the techniques for predicting HFNC outcome remain scarce. Methods: PubMed, EMBASE, and Cochrane Library were searched until April 20, 2021. We included the studies that evaluated the potential predictive value of ROX (respiratory rate-oxygenation) index for HFNC outcome. This meta-analysis determined sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic score, diagnostic odds ratio (DOR), and pooled area under the summary receiver operating characteristic (SROC) curve. Results: We assessed nine studies with 1933 patients, of which 745 patients experienced HFNC failure. This meta-analysis found that sensitivity, specificity, PLR, NLR, diagnostic score, and DOR of ROX index in predicting HFNC failure were 0.67 (95% CI 0.57–0.76), 0.72 (95% CI 0.65–0.78), 2.4 (95% CI 2.0–2.8), 0.46 (95% CI 0.37–0.58), 1.65(95% CI 1.37–1.93), and 5.0 (95% CI 4.0–7.0), respectively. In addition, SROC was 0.75 (95% CI 0.71–0.79). Besides, our subgroup analyses revealed that ROX index had higher sensitivity and specificity for predicting HFNC failure in COVID-19 patients, use the cut-off value > 5, and the acquisition time of other times after receiving HFNC had a greater sensitivity and specificity when compared to 6 h. Conclusions: This study demonstrated that ROX index could function as a novel potential marker to identify patients with a higher risk of HFNC failure. However, the prediction efficiency was moderate, and additional research is required to determine the optimal cut-off value and propel acquisition time of ROX index in the future. PROSPERO registration number: CRD42021240607.

27 November 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
ZTzongbiao tan
zongbiao tan
YWYanrui Wu
Yanrui Wu
YMYang Meng
Yang Meng
CLChuan Liu
Chuan Liu
BDBeiying Deng
Beiying Deng
WDWeiguo Dong
Weiguo Dong
Background: Most studies have primarily focused on assessing the association between diet or exercise patterns and metabolic dysfunction-associated steatotic liver disease (MASLD). This study adopted a more comprehensive approach by introducing the oxidative balance score (OBS) to evaluate the combined effects of diet and lifestyle on the body’s antioxidant ability. Our main objective was to investigate the association between OBS and the burden of MASLD in the United States. Methods: Participants with complete information from 2001 to 2018 were included. In the absence of other definite liver injury factors, the United States fatty liver index (us-FLI) ≥ 30 was used as the diagnostic criterion for MASLD. We first calculated the weighted prevalence for each cycle and stratified it according to demographic and metabolic-related disease characteristics. Subsequently, weighted multiple logistic regression was used to evaluate the relationship between OBS and MASLD. In addition, we explored the body’s inflammatory state and the level of insulin resistance (IR) in mediating OBS and MASLD. Results: From 2001 to 2018, the prevalence of MASLD in the U.S. population as a whole increased from 29.76% to 36.04%, and the rate was higher in people with metabolic-related diseases. Notably, OBS exhibited a negative correlation with MASLD. Participants in the highest tertile of OBS had a significantly lower prevalence of MASLD compared to those in the lowest tertile [OR: 0.72, 95%CI: (0.57, 0.92), p < 0.001]. Moreover, a high OBS is associated with a lower inflammatory state and level of IR. The body’s inflammatory state and IR level mediated the association between OBS and MASLD by 5.2% and 39.7%, respectively (both p < 0.001). Conclusions: In this study, we observed an increasing prevalence of MASLD over the years. A higher OBS was associated with a lower risk of MASLD, especially when OBS ≥ 25. The body’s inflammatory state and IR level mediate the association between OBS and MASLD, but the mechanism needs to be further investigated.

25 January 2021 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JZJunhai Zhen
Junhai Zhen
HBHu Bangchuan
Hu Bangchuan
GSGong Shijin
Gong Shijin
YJYan Jing
Yan Jing
LLLI LI
LI LI
Background: Glucocorticoids are some of the most commonly used drugs for patients with acute respiratory distress syndrome (ARDS). However, the curative effect and side effects of glucocorticoids in treating patients with ARDS remain controversial.Methods: Three databases were searched until 2 July 2020, and randomized controlled trials (RCTs) that compared glucocorticoids versus other therapies in the treatment of ARDS were included in this meta‐analysis. Trial sequential analysis (TSA) was conducted.Results: A total of 14 RCTs with 1362 ARDS patients were assessed. Overall, no statistically significant effect was found on mortality between the glucocorticoid group and the control group of ARDS patients. In the subgroup analysis, no benefit of glucocorticoids for ARDS on mortality was found in trials stratified according to low versus high risk of bias or with vs. without a loading dose. As for the dose and length of therapy, no statistically significant effect was found on mortality with high‐dose, short‐course glucocorticoid therapy. However, lower‐dose and longer‐course therapy with glucocorticoids was found to decrease the mortality of ARDS patients (lower dose: RR = 0.69, 95% CI = 0.51‐0.93, P = .02; longer‐course therapy: RR = 0.60, 95% CI = 0.37‐0.99, P = .04). The TSA showed that more trials are needed to confirm the results.Conclusions: Longer‐ and lower‐dose glucocorticoid treatment may improve the prognosis of ARDS patients, but RCTs with higher quality and larger sample sizes are needed to further clarify the clinical effects of glucocorticoids on ARDS.

14 March 2022 in Vascular
Verified
Journal Article
Closed access
YWYingzheng Weng
Yingzheng Weng
DLDifan Lu
Difan Lu
LTLijiang Tang
Lijiang Tang
YBYizong Bao
Yizong Bao
XCXiaofeng Chen
Xiaofeng Chen
JZJunhai Zhen
Junhai Zhen
Background: Abdominal aortic aneurysm (AAA) is a deadly disease in the elderly population. Currently, the association between single nucleotide polymorphisms (SNPs) and the presence of AAAs has become a hot topic and is a concern for many researchers. Method: We performed a document retrieval in PubMed, EMBASE, and the Cochrane Library (to January 2020). A total of 17 case-control reports on SNPs of AAAs and eight SNPs of correlation factors were selected. All essential data, including race, age, country, criteria of AAA diagnosis, method of AAA measurement, method of genotype detection, name of SNPs, minor allele frequency (MAF), Hardy Weinberg equilibrium (HWE) of the control group, and number of cases and control groups were extracted by two reviewers independently. The fixed-effect model and random-effect model were used to calculate the overall odds ratios (ORs) and 95% confidence intervals (CIs). The association between selected SNPs and the presence of AAAs was evaluated under different genetic models (dominant, codominant, recessive, overdominant, and allele models). Results: A total of 17 articles (sample size ranging from to 42–665 AAA cases and 49–2,297 controls) and 23 SNPs of related factors were identified. Eight SNPs were assessed in at least two studies and were selected for further meta-analysis. We found that the A allele of interleukin (IL)-10 (−1082 G/A) (OR: 1.35, 95% CI: 1.18–1.54, p < 0.0001) was a risk factor for AAAs under random and fixed-effect models. In addition, partial genetic models of these SNPs were confirmed to be related to the presence of AAA. Subgroup analysis revealed that haptoglobin (HP)-1 was a risk factor for AAAs (OR: 1.30, 95% CI: 1.04–1.63, p = 0.02) in the European population. No association was found between the occurrence of AAA and the other SNPs. Conclusion: In our current meta-analysis, we speculated that the genotype distribution of IL-10 (−1082 G/A) may be associated with the emergence of AAA.

1 July 2018
Verified
Journal Article
Closed access
JZJunhai Zhen
Junhai Zhen
LLLi Li
Li Li
JYJing Yan
Jing Yan

1 January 2025 in Digital Health
Verified
Journal Article
Closed access
SZSuqi Zeng
Suqi Zeng
CDChenyu Dong
Chenyu Dong
CLChuan Liu
Chuan Liu
JZJunhai Zhen
Junhai Zhen
YPYu Pu
Yu Pu
WDWeiguo Dong
Weiguo Dong
Aims: This study aimed to evaluate the related research on artificial intelligence (AI) in inflammatory bowel disease (IBD) through bibliometrics analysis and identified the research basis, current hotspots, and future development. Methods: The related literature was acquired from the Web of Science Core Collection (WoSCC) on 31 December 2024. Co-occurrence and cooperation relationship analysis of (cited) authors, institutions, countries, cited journals, references, and keywords in the literature were carried out through CiteSpace 6.1.R6 software and the Online Analysis platform of Literature Metrology. Meanwhile, relevant knowledge maps were drawn, and keywords clustering analysis was performed. Results: According to WoSCC, 1919 authors, 790 research institutions, 184 journals, and 49 countries/regions published 176 AI-related papers in IBD during 1999–2024. The number of papers published has increased significantly since 2019, reaching a maximum by 2023. The United States had the highest number of publications and the closest collaboration with other countries. The clustering analysis showed that the earliest studies focused on “psychometric value” and then moved to “deep learning model,” “intestinal ultrasound,” and “new diagnostic strategies.” Conclusion: This study is the first bibliometric analysis to summarize the current status and to visually reveal the development trends and future research hotspots of the application of AI in IBD. The application of AI in IBD is still in its infancy, and the focus of this field will shift to improving the efficiency of diagnosis and treatment through deep learning techniques, big data-based treatment, and prognosis prediction.